Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.35 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12834762 | 0.87 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL12296586 | 0.85 | HSD11B1 (0.31) | HSD11B1MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL5193595 | 0.84 | THRB (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1771080 | 0.82 | — | — | |
| SCHEMBL26707785 | 0.79 | GRIN2D (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11911862 | 0.79 | PKM (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6504614 | 0.79 | EPHX2 (0.44) | TSHRHSD11B1EPHX2 | |
| SCHEMBL14695704 | 0.77 | TSHR (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2688294 | 0.77 | PKM (0.45) | HSD11B1THRB | |
| SCHEMBL2825436 | 0.77 | GRIN2D (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105385202-A | Waterproof agent for swimming pool | YANTAI SHUNLONG CHEMICAL TECH CO LTD | 2016-03-09 | — | — | CN | claimed |
| CN-104830513-A | Semi-synthetic metal cutting fluid | YANTAI SHUNLONG CHEMICAL ENGINEERING TECHNOLOGY CO LTD | 2015-08-12 | — | — | CN | claimed |
| EP-2231670-A2 | PROCESS FOR THE PREPARATION OF 2-(PRIMARY/SECONDARY AMINO)HYDROCARBYL)- CARBAMOYL-7-OXO-2,6-DIAZA-BICYCLOÝ3.2.0.¨HEPTANE-6-SULFONIC ACID DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009071638-A2 | PROCESS FOR THE PREPARATION OF 2-(PRIMARY/SECONDARY AMINO)HYDROCARBYL)- CARBAMOYL-7-OXO-2,6-DIAZA-BICYCLO[3.2.0.]HEPTANE-6-SULFONIC ACID DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2009-06-11 | — | — | WO | claimed |
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2022-07-05 | — | — | US | disclosed |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| EP-3760607-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | Takasago International Corporation (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399200-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3609866-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | Evonetix Ltd (GB) | 2020-02-19 | — | — | EP | disclosed |
| EP-3405183-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | Arisan Therapeutics Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20020016516-A1 | Hydrocarbon bonded to a carbon atom which is bonded to a hydroxyl group, a methane group, and an adamantane ring; or its protected derivatives; alcohol intermediates for acrylic ester monomers for hydrophilic, adhesive photoresists | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-07 | — | — | US | disclosed |
| US-6344590-B1 | HYDROCARBON BONDED TO A CARBON ATOM WHICH IS BONDED TO A HYDROXYL GROUP, A METHANE GROUP, AND AN ADAMANTANE RING; OR ITS PROTECTED DERIVATIVES; ALCOHOL INTERMEDIATES FOR ACRYLIC ESTER MONOMERS FOR HYDROPHILIC, ADHESIVE PHOTORESISTS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| EP-1055654-A1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH IMIDE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2000-11-29 | — | — | EP | disclosed |
| EP-1043298-A1 | PROCESSES FOR THE PREPARATION OF ALCOHOLS | Daicel Chemical Industries, Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
| EP-0990632-A1 | ADAMANTANEMETHANOL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Daicel Chemical Industries, Ltd. (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-4131656-A | Intermediates for 5-(tertiary alkyl) resorcinol preparation | ELI LILLY AND COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4100170-A | ANTIHYPERTENSIVE AGENTS, MONOAMINE OXIDASE INHIBITORS | PENNWALT CORPORATION (US) | 1978-07-11 | — | — | US | disclosed |
| US-4087410-A | 5-(Tertiary alkyl) resorcinol preparation and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | GRIN2D 3988/4885GRIN3B 2211/4885GRIN1 1774/4885 |
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | NEK4, TENT4A, TCF4 | GRIN2D 1966/4885GRIN3B 772/4885GRIN1 1999/4885 |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | GRIN2D 3969/4885GRIN3B 4274/4885GRIN1 3596/4885 |
| US-20020016516-A1 | Hydrocarbon bonded to a carbon atom which is bonded to a hydroxyl group, a methane group, and an adamantane ring; or its protected derivatives; alcohol intermediates for acrylic ester monomers for hydrophilic, adhesive photoresists | ADH1A, ADGRF1, ADGRE5 | GRIN2D 845/4885GRIN3B 1566/4885GRIN1 484/4885 |
| US-20200399200-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | NEK4, TENT4A, TCF4 | GRIN2D 1966/4885GRIN3B 772/4885GRIN1 1999/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | GRIN2D 3969/4885GRIN3B 4274/4885GRIN1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.